Sign in

You're signed outSign in or to get full access.

Yanan Xu

Research Analyst at Wells Fargo

Yanan Xu's questions to IOVANCE BIOTHERAPEUTICS (IOVA) leadership

Question · Q4 2025

Yanan Xu inquired about the changes in manufacturing success rates over time and the scrap cost for the current quarter.

Answer

Frederick Vogt, Interim CEO and President, stated that scrap cost would be detailed in the 10-K filing and was consistent with prior quarters. He noted that manufacturing success rates are improving, which is driving margin growth. Igor Bilinsky, COO, explained that improvements stem from internal manufacturing enhancements and commercial/medical affairs teams collaborating with Authorized Treatment Centers (ATCs) to optimize tumor procurement.

Ask follow-up questions

Fintool

Fintool can predict IOVANCE BIOTHERAPEUTICS logo IOVA's earnings beat/miss a week before the call